Immunomedics Develops New Antibody-Drug Conjugate for Hematologic Cancer Therapy

ORLANDO, Fla., Dec. 7, 2010 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company’s humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses [...] http://bit.ly/ecIIqV